DaVita reports Q2 2026 revenue of $3.55B, net income $265M, and raises 2026 guidance for income and cash flow.

DaVita Inc. announced strong Q2 2026 results with consolidated revenues of $3.554 billion and net income attributable to DaVita of $265 million, up from $199 million in Q2 2025. Operating income rose to $579 million, supported by increased dialysis treatments and improved patient outcomes. The company repurchased 2.2 million shares and secured a $500 million term loan to strengthen its balance sheet. For 2026, DaVita projects adjusted operating income between $2.15 billion and $2.25 billion, adjusted diluted net income per share of $14.10 to $15.20, and free cash flow of $1 billion to $1.25 billion, reflecting confidence in ongoing growth and innovation in kidney care.